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Methods: Human cartilage explants were cultured in the pres-
ence or absence of the catabolic cytokines oncostatin M (OSM)
and tumor necrosis factor alpha (TNFα). Fragments originating
from aggrecanase and MMP-mediated cleavage of aggrecan and
type II collagen and released into the supernatant was determined
using a range of neo-epitope speciﬁc immunoassays; (1) sandwich
342FFGVG-G2 ELISA, (2) competition NITEGE373ELISA (3) sand-
wich G1-NITEGE373 ELISA (4) competition 374ARGSV ELISA,
and (5) sandwich 374ARGSV-G2 ELISA all detecting aggrecan
fragments, and (6) sandwich CTX-II ELISA, which is speciﬁc for
the cross-linked neo-epitope EKGPDPxEKGPDP originating from
the C-telopeptide of type II collagen.
Results: We found that quantitatively the accumulated release of
aggrecanase- and MMP-derived aggrecan fragments was similar
in bovine and human cultures of articular cartilage upon stimula-
tion with catabolic cytoikines. However, in human cultures these
fragments were continuously released during all phases of the
21 day culturing period, whereas in bovine cultures MMP-derived
fragments were only observed in the late phase (day 16-21) and
aggrecanase-derived fragments in the early and mid phase.
Conclusions: Our data conﬁrm that major differences in bovine
and human processing of articular cartilage exist in response to
catabolic cytokines. This suggest that careful consideration should
given to the application of this ex vivo model in drug screening
programmes.
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Purpose: Progressive loss of articular cartilage is a central hall-
mark in many joint disease, however, the relative importance of
individual proteolytic pathways leading to cartilage erosion is at
present unknown. In particular, the metabolic response induced by
the inhibition of MMPs remains to be investigated in appropriate
model systems, which also includes assessment of aggrecanase-
derived matrix degradation. We therefore investigated the time-
dependant release ex vivo of MMP- and aggrecanase-derived
fragments of aggrecan and type II collagen into the supernatant
of bovine cartilage explants cultures using neo-epitope speciﬁc
immunoassays, and to associate the release of these fragments
with the activity of proteolytic enzymes using inhibitors.
Methods: Bovine cartilage explants were cultured in the presence
or absence of the catabolic cytokines oncostatin M (OSM) and
tumor necrosis factor alpha (TNFα). In parallel, explants were co-
cultured with protease inhibitors such as GM6001, TIMP1, TIMP2
and TIMP3. Fragments originating from aggrecanase and MMP-
mediated cleavage of aggrecan and type II collagen and released
into the supernatant was determined using a range of neo-epitope
speciﬁc immunoassays; (1) sandwich 342FFGVG-G2 ELISA, (2)
competition NITEGE373ELISA (3) sandwich G1-NITEGE373 ELISA
(4) competition 374ARGSV ELISA, and (5) sandwich 374ARGSV-
G2 ELISA all detecting aggrecan fragments, and (6) sandwich
CTX-II ELISA, which is speciﬁc for the cross-linked neo-epitope
EKGPDPxEKGPDP originating from the C-telopeptide of type II
collagen.
Results: We found that (1) aggrecanase-derived aggrecan frag-
ments are released in the early (day 2-7) and mid phase (day
9-14) into the supernatant from bovine explants cultures stimu-
lated with catabolic cytokines, (2) the release of NITEGE373 neo-
epitopes are delayed compared to the corresponding 374ARGSV
fragments, (3) the MMP inhibitor GM6001 did not reduce the
release of aggrecanase-derived fragment, but induced a further
delay in the release of these fragments, (4) no signiﬁcant differ-
ences between aggrecan proﬁle obtained with competitive assays
vs corresponding sandwich assays could be detected, ﬁnally (5)
the MMP-derived aggrecan and type II collagen fragments were
released in the late phase (day 16-21) only.
Conclusions: Our data support the model, that aggrecanases
and MMPs act independently in the processing of the aggrecan
molecules, and furthermore that suppression of MMP-activity had
little if any effect on the quantity of aggrecanase-derived fragments
released from explants cultures.
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Purpose: Osteoarthritis (OA) is a disease that affects the en-
tire articular joint, with both changes to the bone and cartilage
compartments.
Optimal biomechanical properties are pivotal for maintenance of
joint integrity and function. Altered biomechanical properties of
bone and cartilage are observed in OA disease and might add to
worsening of disease.
We investigated biomechanical properties of the bone and carti-
lage compartments in healthy and affected rat knees from an OA
model with combined traumatic knee surgery and increased bone
turnover.
Methods: Two groups each of 10 6-months old rats were sub-
jected to a combined ovariectomy and partial medial meniscec-
tomy (OVX+MNX) or sham surgery (SHAM).
Animals were sacriﬁced 8 weeks after surgery, and one tibia was
processed for biomechanical indentation testing. The tibias were
cast in Acrylﬁx-mould with the shaft ﬁxated in the mould and the
tibial plateau protruding.
Indentation test was performed centrally on the medial part of the
tibial plateau (Figure 1). An indenter area of 0.78 mm2 and a ﬁxed
Figure 1. AC: Articular cartilage; SBP: Subchondral bone plate; GP: Growth
plate; TB: Trabecular bone.
